Differences in p53 status significantly influence the cellular response and cell survival to 1,25-dihydroxyvitamin D3-metformin cotreatment in colorectal cancer cells-Reference-Cited by-同舟云学术

Differences in p53 status significantly influence the cellular response and cell survival to 1,25-dihydroxyvitamin D3-metformin cotreatment in colorectal cancer cells

Published:2017-07-13 Issue:11 Volume:56 Page:2486-2498
ISSN:0899-1987
Container-title:Molecular Carcinogenesis
language:en
Short-container-title:Mol Carcinog

Author:

Abu el Maaty Mohamed A.¹^ORCID,Strassburger Wendy¹,Qaiser Tooba¹,Dabiri Yasamin¹,Wölfl Stefan¹

Affiliation:

1. Institute of Pharmacy and Molecular Biotechnology; University of Heidelberg; Heidelberg Germany

Funder

Bundesinstitut für Risikobewertung

Deutscher Akademischer Austausch Dienst Kairo

Publisher

Wiley

Subject

Cancer Research,Molecular Biology

Reference45 articles.

1. Molecular origins of cancer: molecular basis of colorectal cancer;Markowitz;N Engl J Med,2009

2. P53 Research: the past thirty years and the next thirty years;Lane;Cold Spring Harb Perspect Biol,2010

3. Mutant p53 in cancer: new functions and therapeutic opportunities;Muller;Cancer Cell,2014

4. P53-dependent apoptosis modulates the cytotoxicity of anticancer agents;Lowe;Cell,1993

5. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline;Fan;Cancer Res,1995

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vitamin D and colorectal cancer;Feldman and Pike's Vitamin D;2024

2. Repurposing Metabolic Inhibitors in the Treatment of Colon Adenocarcinoma Patient-Derived Models;Cells;2023-12-18

3. From molecular basis to clinical insights: a challenging future for the vitamin D endocrine system in colorectal cancer;The FEBS Journal;2023-09-20

4. Enhanced in vitro tumoricidal effects of 5-Fluorouracil, thymoquinone, and active vitamin D3 triple therapy against colon cancer cells by attenuating the PI3K/AKT/mTOR pathway;Life Sciences;2022-05

5. Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1/GSK-3 pathway inhibitors, nutraceuticals and alter metabolic properties;Aging;2022-04-27